AuditMed: A Single-File, Browser-Based Clinical Evidence Audit Platform — Architecture, Stress-Test Results, and Proposed Applications in Drug Informatics and Pharmacy Education

David J. Ferguson, MS, BCMAS, MRSC, MRSB, RSci

Correspondence: david.ferguson@bison.howard.edu
Platform access: https://auditmed9.onrender.com/
For research and educational purposes only.

Abstract

Background

Clinical pharmacists, trainees, and educators rely on multi-database literature retrieval and structured evidence synthesis to answer drug-information questions. Existing workflows require navigation across PubMed, DailyMed, LactMed, interaction checkers, and specialty guideline repositories with manual de-duplication, appraisal, and synthesis. Commercial platforms that integrate these functions are costly and often unavailable in community, rural, and international training contexts.

Objective

This report describes the architecture of AuditMed, a single-file, browser-based clinical evidence audit platform, and reports preliminary stress-test results against a complex multi-morbidity case corpus. AuditMed is intended for research and educational use and is not a substitute for clinical judgment or validated commercial clinical decision-support systems.

Methods

AuditMed integrates nineteen free, publicly available clinical and biomedical application programming interfaces into a six-stage Search → Select → Parse → Analyze → Infer → Create pipeline and supports browser-local patient-case ingestion with regex-based HIPAA Safe Harbor de-identification. Preliminary stress-testing was conducted against eleven cases (Cases 30 through 40) from the Complex Clinical Case Compendium Software Validation Suite, each featuring over twenty concurrent active disease states. For each case, the one-click inference pipeline was executed with default settings and the full Clinical Inference Report was captured verbatim. No retrieval-sensitivity, synthesis-fidelity, or time-to-answer endpoints were pre-specified; the exercise was qualitative and oriented toward pipeline behavior under extreme multi-morbidity.

Results

The pipeline completed without fatal errors for all eleven cases and produced a structured Clinical Inference Report in each instance. Quantitative-finding detection performed as designed for hematologic parameters and cardiac biomarkers. Two parser defects were identified and are reproduced in the

appendix: an age-as-fever regex-precedence defect affecting seven cases and a diagnosis-versus-medication parsing defect affecting one case. Evidence-linkage rate varied from zero evidence-linked statements in seven cases to eleven in one case, reflecting dependence of the inference layer on MeSH-indexed literature coverage of the specific case diagnoses.

Conclusions

AuditMed is an early-stage, open-source platform whose value at this stage is in providing a free, transparent, auditable workflow for multi-source evidence synthesis with explicit uncertainty flagging. The preliminary results document both robust end-to-end completion under extreme case complexity and specific, reproducible parser defects that will be addressed before formal evaluation. Planned evaluation studies are described.

Keywords

clinical informatics; drug information; evidence synthesis; pharmacy education; open-source software; browser-based application; clinical decision support; PRISMA; GRADE.

1. Introduction

1.1 Background

Evidence-based pharmacy practice requires retrieval, appraisal, and synthesis of information from heterogeneous clinical databases. A typical drug-information question may require consultation of primary literature (PubMed, Europe PMC), FDA-approved labeling (DailyMed), lactation safety data (LactMed), patient-facing education (MedlinePlus), drug classification (RxNorm, AHFS), interaction checking (Drugs.com, Lexi-Interact), clinical trial registries (ClinicalTrials.gov), and specialty guidelines (Cochrane, professional society publications). Each resource has its own search syntax, data structure, and output format. The cognitive burden of moving across these tools is documented and can limit the depth of evidence review performed under time pressure.

Commercial platforms that integrate several of these resources — UpToDate, Lexicomp, Micromedex, DynaMed — are widely adopted but not universally accessible. Institutional licenses are expensive and often do not extend to community or rural practice sites, to international training programs, or to independent educational projects. Individual subscriptions place a barrier in front of pharmacy students, early-career pharmacists, and clinical educators in resource-limited contexts.

A parallel development in recent years has been the emergence of large language model (LLM) based clinical assistants. These systems can generate readable summaries across multiple queries in seconds but present specific risks: source fabrication, inability to trace each output claim to an original citation, susceptibility to prompt-injection, and opaque reasoning chains that complicate appraisal. For drug-information and clinical-education use, a system that combines the breadth of LLM-style synthesis with the source fidelity of traditional retrieval tools is attractive, provided it foregrounds uncertainty and flags claims requiring external verification.

A third thread concerns how students learn to think critically in clinical settings. Scoping reviews of the health-professions education literature return a consistent finding: after decades of work in nursing, medicine, and the allied health professions, there is no shared definition of critical thinking, no agreed instrument for measuring it, and no consensus on how it should be taught [1–3]. Where durable educational gains have been reported, they have tended to come from tools that let students work with real evidence in their own specialty, rather than from tools that try to automate the appraisal itself [4–9].

Taken together, these three threads — the fragmented database landscape, the access gap for resource-constrained users, and the unsettled pedagogy of critical thinking in clinical education — point toward a specific set of design requirements: integrate across the sources a clinician actually consults; keep retrieved evidence visible rather than absorb it into generated prose; make uncertainty easy to see rather than easy to overlook; and run without a paid license so that access is not the rate-limiting step.

1.2 Objective

This report describes the architecture of AuditMed, a single-file browser-based clinical evidence audit platform designed to meet the four design requirements above. It also reports preliminary stress-test results against a complex multi-morbidity case corpus and outlines proposed applications pending formal evaluation. This report is a platform-description and preliminary-stress-test manuscript; it is not a validation study. Formal evaluation studies are described in the Future Directions section.

2. Platform Description

2.1 Design Principles

AuditMed is designed around four principles, each corresponding to one of the design requirements derived above.

- Client-first execution. All user-facing logic runs in the browser. A user with a static copy of the HTML file and an internet connection can perform retrieval, appraisal, and synthesis without a local server. An accompanying Node.js server handles user authentication, password reset, and anonymous usage analytics only.

- Free and open-access APIs only. Every integrated data source is publicly available without a paid license or mandatory API key, with the single exception of an optional DrugBank Clinical API upgrade. Without a DrugBank key, the platform uses the free UniChem identifier-resolution pathway.

- Source fidelity. Each output claim is tagged to an original record (PubMed identifier, DOI, or URL) so that users can inspect the underlying document. Direct quotation is limited to short phrases where exact wording carries meaning; most output is paraphrased.

- Epistemic humility. The platform distinguishes between findings with high-confidence evidence support, findings with moderate support, and findings for which retrieved evidence did not address the question. The third category is flagged explicitly and paired with verification steps directing the user to external authoritative sources.

2.2 Technical Stack and Licensing

AuditMed is implemented as a single HTML document combining HTML, CSS, and vanilla JavaScript, with no build step required. Browser-side features are executed through standard Web APIs; persistent case storage uses the browser IndexedDB, which is device-local. An accompanying Node.js server provides user authentication, password reset, anonymous usage analytics, and administrative endpoints; it does not transmit case data and does not call the integrated clinical APIs on the user's behalf.

AuditMed is an open-source platform: it is free to use, is hosted at a publicly accessible URL, does not require any paid subscription for default operation, does not display advertisements, and does not collect identifiable user data beyond that required for authentication. The underlying source code is not distributed under a conventional open-source license at this time and is not currently posted to a public

code repository; the term "open source" is used here in the sense of open access and open use, not in the sense of an Open Source Initiative–approved software license. A transition to a formal open-source code license is a planned governance step (see Future Directions).

2.3 The Six-Stage Evidence Pipeline

The central workflow is the Search → Select → Parse → Analyze → Infer → Create pipeline. Each stage is inspectable, and the user may override auto-selection at stage 4.5 to refine the evidence base before synthesis.

Stage	Function	User Role
1. Search	Query 19 APIs in parallel; expand until ≥100 unique sources or retries exhausted	Enter clinical question or auto-derive from case diagnoses
2. Select	De-duplicate by PMID/DOI/title; score by source tier, recency, metadata completeness; retain top-N	Review auto-selection at stage 4.5 checkpoint
3. Parse	Extract section text, key findings, statistical expressions, and recommendation-type sentences	None (automatic)
4. Analyze	Compute theme frequency, temporal patterns, methodology distribution, journal distribution, and cross-source convergence	None (automatic)
5. Infer	Generate convergent findings, divergent findings, evidence gaps, and case-grounded inferential findings with confidence tags	None (automatic)
6. Create	Assemble structured output in one of nine formats with explicit source citations and verification steps	Choose output format; export

2.4 Integrated Data Sources

AuditMed integrates nineteen application programming interfaces, selected to cover the major dimensions of clinical drug information: primary literature, trials, labeling, safety, classification, and interaction data. Integrated sources include PubMed, Europe PMC, CrossRef, OpenAlex, Cochrane Library, medRxiv/bioRxiv, WHO IRIS, Unpaywall, ClinicalTrials.gov, openFDA (labels, FAERS), DailyMed, LactMed, MedlinePlus, RxNorm/RxClass (with AHFS therapeutic classifications referenced via RxClass), DrugBank (via UniChem for free identifier resolution, with an optional paid Clinical API upgrade), and general web search (SerpAPI/Brave, optional).

An important caveat: Drugs.com, Lexi-Interact, and GlobalRPh do not expose public APIs. AuditMed integrates these as direct-linked references rather than as parsed data sources. The platform therefore

provides the user with immediate access to these tools alongside its own outputs but does not mine their content programmatically. For queries requiring a comprehensive interaction screen, AuditMed should be used as a complement to, not a replacement for, an institutional interaction checker.

2.5 Patient-Case Ingestion and De-identification

The Clinical Acumen module accepts patient-case PDFs (H&P, SOAP notes, discharge summaries) and plain-text files. The ingestion pipeline extracts text page-by-page, applies a regex-based de-identification layer covering the eighteen categories of protected health information defined by the HIPAA Safe Harbor method [11], detects multi-case documents, and parses each case for demographics, vital signs, laboratory values, medications, and documented diagnoses. Parsed output is stored in a browser-local IndexedDB case library that persists across sessions but never leaves the user's device.

Regex-based de-identification has structural limits: it cannot reliably catch unique identifying numbers embedded in free text, dates in non-standard formats, or rare diagnoses that themselves identify a patient in small populations. The de-identification layer should therefore be treated as best-effort preprocessing, not as a validated PHI-removal tool. Users remain responsible for ensuring that uploaded documents comply with institutional privacy policies and local regulations.

2.6 The Clinical Inference Layer

The component that distinguishes AuditMed from a simple federated search tool is the inference layer, which takes parsed case data and retrieved evidence and produces case-grounded inferential findings and verification steps.

2.6.1 Deriving clinical findings from case data

Pattern-based scanning of the parsed case recognizes findings in eight domains: renal (elevated creatinine with nephrotoxic or renally-adjusted medication context), electrolyte (hyper- and hypokalemia, hyponatremia with medication context), cardiac (elevated troponin, elevated BNP), metabolic (elevated lactate with metformin-accumulation awareness), hematologic (severe anemia, severe thrombocytopenia including HIT consideration when heparin is present), infectious (leukocytosis with procalcitonin when available; fever), hemodynamic/respiratory (hypotension with shock differential prompt; hypoxia), and drug–drug interactions (a curated set of seven high-risk pairs). Each detected finding carries a category, severity (critical / high / moderate / mild), a clinical implication in natural language, and any related contextual flags from the medication list. The pattern library does not currently cover hepatic markers, endocrine patterns, pediatric-specific findings, or geriatric-specific considerations; expansion across these domains is a priority for future development.

2.6.2 Extracting evidence-grounded statements

For each retrieved source, the platform decomposes available text (results, conclusion, and background sections where parseable) into sentences and classifies each sentence by type (recommendation, association, quantitative, comparative, null-finding, descriptive) and by evidence classification (RCT

evidence, meta-analytic evidence, guideline, observational evidence). Each extracted statement carries a strength tag derived from its classification: guideline and meta-analytic sources receive "high," RCT-classified sources receive "moderate-high," observational sources receive "moderate," and unclassified sources receive "limited." The "limited" default is conservative and applies to any source not recognized by the classifier regardless of actual quality; this can underweight high-quality sources whose metadata the classifier did not recognize.

2.6.3 Building inferential findings

Inferential findings are the cross-product of case-derived clinical findings and evidence-grounded statements. For each clinical finding, the platform searches for evidence statements whose text addresses the relevant category. If matching evidence is found, the finding is labeled "evidence-linked" and supporting statements are attached with citations. If no matching evidence is found, the finding is labeled "unmatched-finding" and flagged for external verification. Two additional classes are also produced: "diagnosis-evidence" findings map each working diagnosis to its strongest retrieved evidence, and "medication-evidence" findings do the same for documented medications.

2.6.4 Generating verification steps

The verification-step generator operationalizes the epistemic-humility principle. Every detected clinical finding, evidence-linked or not, generates a verification step; priority is assigned jointly by the severity of the underlying finding and by whether retrieved evidence addresses it. Critical-severity findings (for example, elevated troponin) generate an immediate-priority cardiac-workup step; high-severity findings (for example, elevated BNP or severe thrombocytopenia) generate an urgent-priority step. Every unmatched finding additionally generates a routine-priority external-verification step pointing to UpToDate, DynaMed, specialty society guidelines, or DailyMed. Additional steps fire automatically when polypharmacy is present (≥3 medications) and as a standing final item reminding the user that clinical decisions remain the responsibility of the treating clinician. The verification-step rules as stated here reflect the behavior observed in the stress-test outputs (Appendix A): a spurious finding generated by an upstream parser defect will still receive a priority tag consistent with the rule above, which is why defective inputs can propagate into clinically implausible verification steps. This behavior is by design — the verification layer does not second-guess the clinical-finding layer — and it is one reason the parser defects documented in the Results are operationally important rather than cosmetic.

3. Methods

3.1 Study design

This was an exploratory, qualitative stress test of the AuditMed case-ingestion and one-click inference workflow under conditions of extreme multi-morbidity. The study was not a metric-driven validation and did not pre-specify retrieval-sensitivity, synthesis-fidelity, inter-rater-agreement, or time-to-answer

endpoints. Outputs were not compared against reference answers authored by clinical experts. The exercise is best characterized as software stress-testing and qualitative observation of pipeline behavior.

3.2 Case corpus

Cases were drawn from the Complex Clinical Case Compendium Software Validation Suite (April 2026), a forty-case corpus of synthetic multi-morbidity vignettes explicitly designated for software validation purposes only and not for clinical decision-making. The source document is a synthetic corpus; no real patient data were used in its construction and no protected health information was present in the cases evaluated. Cases 30 through 40 were selected as a contiguous eleven-case block at the upper end of the corpus, each case featuring over twenty concurrent active disease states with documented multidisciplinary-team involvement. This subset was chosen to exercise pipeline behavior under extreme polypharmacy, multi-organ-system derangement, and overlapping competing treatment priorities.

3.3 Platform configuration

The AuditMed platform was run at the public deployment (https://auditmed9.onrender.com/) using default settings. The AuditMed Evidence Engine (AEE) was used for all syntheses; no LLM augmentation was configured. No DrugBank Clinical API key was supplied. All nineteen integrated APIs were enabled at defaults. The pipeline was executed in its one-click configuration, with default top-12 auto-selection and no manual source refinement at stage 4.5.

3.4 Procedure

For each of the eleven cases, the source case description was saved as plain text, ingested through the Clinical Acumen module, and stored in the browser-local case library. The one-click inference pipeline was then invoked from the library. The generated Clinical Inference Report was captured verbatim in plain text and preserved without post-hoc editing. Reports are reproduced in Appendix A in the order generated.

3.5 Observations captured

For each case, the following were recorded from the generated report: the demographic field as parsed by the platform, the diagnosis list as parsed, the number of laboratory values and medications extracted, the set of pattern-matched clinical findings with severity tags, the number of evidence-linked statements produced by the inference layer, the overall GRADE tier assigned, the number of verification steps generated, and any visible parser artefacts. Summary comparisons across cases are presented in Section 4.

3.6 Ethics and data availability

All cases used in this work are synthetic, drawn from a corpus explicitly designated for software validation, and contain no real patient data. Institutional Review Board review was therefore not required; this work does not constitute human subjects research. The Complex Clinical Case Compendium

Software Validation Suite is a self-contained corpus; the eleven case descriptions used in this work are reproduced verbatim in Appendix A of this manuscript alongside the verbatim platform outputs, and no separate data request is required to reproduce the analysis. The verbatim Clinical Inference Reports generated by AuditMed for all eleven cases are likewise reproduced in Appendix A and constitute the full primary data for this report. No additional supplementary datasets are withheld. Planned evaluation studies involving human participants (see Future Directions) will be submitted for IRB review prior to enrollment.

4. Results

4.1 End-to-end completion

The pipeline completed without fatal errors for all eleven cases and produced a structured Clinical Inference Report in each instance. This indicates that the end-to-end one-click workflow is robust to extreme multi-pathology inputs in the sense that it does not crash; it does not establish correctness of intermediate parsing or inference steps, which are addressed separately below.

4.2 Quantitative-finding detection

Quantitative-finding detection performed as designed for hematologic parameters: severe anemia and severe thrombocytopenia were correctly flagged in Cases 35, 36, 39, and 40. Cardiac-biomarker detection also performed as designed: elevated troponin was flagged in Cases 33 and 34, and elevated BNP was flagged in Cases 34, 36, and 39. The severity tags attached to these findings (critical for troponin, high for BNP, high for severe anemia, high for severe thrombocytopenia) matched the rules described in Section 2.6.4 and drove priority-appropriate verification steps (immediate for troponin, urgent for BNP and severe thrombocytopenia, immediate for severe anemia).

4.3 Parser defects identified

Two reproducible parser defects were identified.

Age-as-fever defect. The fever-detection regex was not adequately anchored to temperature-unit context or to an age-field exclusion, and the patient's age from the demographics field was misclassified as a body-temperature reading in Cases 31, 32, 33, 34, 37, 38, and 39. This produced spurious fever findings at physiologically impossible values (for example, "Fever (68°C)" in Case 33 and "Fever (70°C)" in Case 39). The verification layer then generated routine-priority external-verification steps on the basis of these spurious findings, consistent with the rule described in Section 2.6.4. No immediate- or urgent-priority steps were triggered by the spurious fever findings because the fever severity classifier assigned them moderate severity, which is itself a downstream effect of the same defect: a genuine fever of 68°C would of course be critical, but the severity classifier appears to apply fixed temperature thresholds without reconciling them against physiologic plausibility.

Diagnosis-versus-medication parsing defect. The diagnosis extractor did not consistently distinguish diagnosis sentences from medication sentences in free-text case source documents. This was most visible in Case 38, whose parsed diagnosis list contained substrings such as "gabapentin 600 TID (spasm adjunct), dantrolene PRN" that had been lifted from the medication paragraph of the source case. This defect did not propagate into spurious severity-tagged findings, but it did degrade the semantic quality of the diagnosis list used to seed subsequent API queries.

4.4 Evidence-linkage rate

Evidence-linkage rate varied widely across cases, from zero evidence-linked statements in seven of eleven cases (Cases 30, 31, 35, 36, 38, 39, and 40) to eleven evidence-linked statements for Case 33 (immune-checkpoint-inhibitor triple toxicity). This variability reflects dependence of the inference layer on MeSH-indexed literature coverage of the specific case diagnoses, and suggests that the current literature-matching pass is too narrow for highly multi-morbid cases. The observation motivates a specific parser and matcher redesign rather than a general claim about platform capability; in particular, broader query expansion and softer matching on diagnosis synonyms are candidate interventions. Absolute source-retrieval counts per case ranged from seven to twelve, indicating that the breadth of retrieval itself was adequate and that the bottleneck was at the semantic-matching step between retrieved sources and case findings.

4.5 GRADE tier distribution

Ten of eleven cases received an overall GRADE tier of LOW; one case (Case 33) received MODERATE. The MODERATE assignment was driven by the presence of three systematic reviews or meta-analyses and one RCT among the retrieved sources together with two high-confidence inferences. No case received a HIGH tier, which is consistent with the conservative default (Section 2.6.2) and with the low evidence-linkage rate observed in most cases.

4.6 Verification-step generation

Verification steps were generated for every case, ranging from three steps in the simplest reports to eight in the most complex. Every case received the standing polypharmacy reminder (all cases documented at least three medications) and the standing final item directing the user to cross-verify against institutional protocols and current product labeling. Priority-tagged steps were generated appropriately for correctly detected findings and, as noted in Section 4.3, were also generated on the basis of spurious fever findings; the spurious-finding steps are themselves cosmetically harmless (they point users to external authoritative resources) but they nonetheless represent noise in the report.

4.7 Summary comparisons across cases

Table 1 summarizes the principal similarities and differences across the eleven Clinical Inference Reports generated. Similarities dominate at the structural level: every report contained the expected six structural

sections (reasoning chain, inferential findings, verification steps, evidence-based recommendations, GRADE tier, reference list), every report was produced without pipeline failure, and every report received a conservative GRADE tier (LOW or MODERATE). Differences concentrated at three specific points: the count of pattern-matched clinical findings (which varied with the laboratory-value density of the source case), the evidence-linkage rate (which varied with MeSH coverage of the case diagnoses), and the presence or absence of the two reproducible parser defects.

Table 1. Summary comparison of Clinical Inference Reports across Cases 30–40 of the Complex Clinical Case Compendium Software Validation Suite.

Case	Clinical descriptor (abbrev.)	Labs parsed	Meds parsed	Clin. findings (sev.)	Evid-link ed stmts	Sources retrieved	GRADE tier	Parser defects
30	Gastroparesis / intestinal failure / porphyria	12	6	1 (mod/mild)	0	7	LOW	None
31	Sarcoidosis / CHB / hypercalcemia	3	4	1 (mod/mild)	0	10	LOW	Age→fever
32	POEMS / Castleman / PAH	6	2	1 (mod/mild)	7	12	LOW	Age→fever
33	ICI triple toxicity (myocarditis + myositis + MG)	6	4	2 (1 crit, 1 mod)	11	12	MODERATE	Age→fever
34	EGPA / eosinophilic myocarditis / status asthmaticus	4	5	3 (1 crit, 1 high, 1 mod)	1	9	LOW	Age→fever
35	PNH / Budd-Chiari / meningococcal sepsis	7	3	2 (1 crit, 1 high)	0	9	LOW	None
36	SAA + PNH / Jehovah's Witness	5	5	3 (1 crit, 2 high)	0	11	LOW	None
37	IgG4-RD mimicking cholangiocarcinoma	6	3	1 (mod/mild)	1	12	LOW	Age→fever
38	Stiff-person syndrome / thymic carcinoid	2	8	1 (mod/mild)	0	10	LOW	Age→fever; Dx→Rx
39	Acquired hemophilia A / mechanical valve	5	3	3 (1 crit, 1 high, 1 mod)	0	9	LOW	Age→fever
40	TA-TMA / chronic GVHD / BOS / AIHA	4	9	2 (1 crit, 1 high)	0	8	LOW	None

Abbreviations: CHB, complete heart block; PAH, pulmonary arterial hypertension; MG, myasthenia gravis; EGPA, eosinophilic granulomatosis with polyangiitis; PNH, paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; IgG4-RD, IgG4-related disease; TA-TMA, transplant-associated thrombotic microangiopathy; GVHD, graft-versus-host disease; BOS, bronchiolitis obliterans syndrome; AIHA, autoimmune hemolytic anemia; Age→fever, age field misclassified as body temperature; Dx→Rx, medication string captured in diagnosis list.

5. Proposed Applications

The applications described in this section are positioned as proposed, not validated. Each application describes a workflow in which AuditMed could plausibly be useful pending the evaluation studies outlined in Section 7. No claims in this section should be read as established.

5.1 Drug-informatics practice

As a first-pass tool for drug-information consults, AuditMed's parallel API query returns a unified source table across its nineteen integrated databases in a single query. The source-review step allows the user to deselect irrelevant results and focus synthesis on sources meeting internal criteria. The nine output formats map to the structure of common consult deliverables. The explicit handling of evidence gaps — flagged rather than paved over — is aligned with drug-information practice standards that require clinicians to indicate when an answer exceeds the available evidence rather than extrapolate.

For pharmacovigilance signal triage, AuditMed's integration of openFDA's adverse event reporting system alongside PubMed and DailyMed provides a structured first pass in which a user investigating a potential drug-adverse-event association can retrieve the top FAERS signals, associated literature, current DailyMed labeling, and lactation and renal-dosing implications in one workflow. AuditMed does not replace dedicated pharmacovigilance systems. For medication-reconciliation decision support, the case-ingestion pipeline parses medication lists and cross-references them against a curated interaction pattern library; for patients on ≥3 medications, a polypharmacy verification step is generated automatically. This is a prompt to run a dedicated interaction screen, not a substitute for one.

5.2 Systematic-review scoping

AuditMed's Systematic Review output format produces a PRISMA-style flow, a study-type breakdown, a methodology distribution, a temporal distribution, and risk-of-bias placeholders populated from retrieved evidence. This output may be useful as a scoping artefact prior to a formal systematic review registered with PROSPERO. AuditMed does not replace dedicated systematic-review software (such as Covidence or Rayyan) and should not be used as the primary retrieval engine for a published systematic review: its API breadth is narrower than Embase or CINAHL. The appropriate framing is as a complement for the scoping phase, not as a retrieval engine for the review itself.

5.3 Pharmacy education

In drug-information course laboratories, AuditMed can serve as a laboratory environment in which students receive a clinical question, perform retrieval, review auto-selected sources, refine the selection, and compose a written response. Instructors can grade student selection decisions in a way that is more visible than when retrieval is performed in a native database interface. The per-source confidence and strength tagging gives instructors a vocabulary to teach source appraisal.

During Advanced Pharmacy Practice Experience (APPE) rotations, AuditMed's one-click inference workflow produces a structured evidence map for a case that the student can review and expand upon as a scaffold, not a substitute, for their own literature search. The inferential-findings and verification-steps sections provide preceptors with concrete artefacts against which to direct questioning. For NAPLEX preparation, AuditMed functions as a reference tool rather than a primary study resource. MPJE review is not well served by the platform, since most MPJE content is state-specific regulation rather than drug information.

5.4 Resource-limited and international settings

The free-and-open-access design is relevant to pharmacy education programs in resource-limited settings that cannot afford commercial drug-information subscriptions. Faculty in such settings can use the platform directly at its public URL. This does not match the depth of a commercial platform; it provides a free alternative where no tool would otherwise be available. A multilingual extension — translation of the platform scaffolding and support for Spanish- and French-language resources available through the WHO IRIS catalog — is a planned next step and would extend utility to pharmacy programs in Latin America and francophone Africa.

6. Limitations

6.1 Not a substitute for clinical judgment

AuditMed is for research and educational use. Platform outputs are not intended to serve as the basis for individual patient care decisions. Every Clinical Inference Report ends with a safety step reminding the user to cross-verify against institutional protocols, current product labeling, and specialty-specific guidelines. Institutions considering AuditMed as a teaching tool should reinforce this boundary with their trainees.

6.2 API coverage is narrower than commercial platforms

The nineteen integrated APIs cover a broad swath of publicly available clinical information but do not include Embase, CINAHL, Scopus, or other subscription-based databases. For systematic reviews requiring comprehensive database coverage, AuditMed should be used as a scoping or supplementary tool rather than as the primary search engine.

6.3 Inference engine is pattern-based, not causal

The inferential-findings layer uses regular-expression and keyword-based pattern matching to link case data to evidence. This approach is fast and auditable but cannot detect semantic equivalence between paraphrased clinical concepts, cannot reliably handle negation (for example, "no evidence of myocardial infarction" may be misclassified), and does not perform causal reasoning. Confidence tags are calibrated

to this limitation: a "high-confidence" inference is one with abundant text-matching evidence, not one with verified causal linkage.

6.4 De-identification is best-effort

The regex-based de-identification pipeline covers the eighteen HIPAA Safe Harbor categories but cannot guarantee complete PHI removal (see Section 2.5). AuditMed should not be considered a validated PHI-removal tool for IRB purposes at this time. Browser-local storage ensures that case data never leave the user's device, but this does not relieve the user of institutional responsibilities.

6.5 Parser defects present in current stress-test outputs

As reported in Section 4.3, two reproducible parser defects were identified: an age-as-fever regex-precedence defect affecting seven of eleven cases and a diagnosis-versus-medication parsing defect affecting one case. These defects do not affect end-to-end completion of the pipeline but do degrade the semantic quality of the outputs. Both defects will be addressed in the parser-layer fixes that precede the formal evaluation studies described in Section 7.

6.6 Validation status

AuditMed has undergone preliminary software stress-testing against eleven complex multi-morbidity cases as described in this report. It has not undergone formal validation against retrieval benchmarks (for example, retrieval sensitivity on a curated query set) or synthesis benchmarks (for example, blinded comparison of platform-generated synthesis against expert-authored answers). The pipeline includes an internal structural-integrity harness that verifies software correctness across nine output formats; this harness tests software correctness, not clinical validity.

6.7 LLM-augmentation is optional and opt-in

The default AuditMed Evidence Engine (AEE) is a deterministic, in-browser NLP synthesis engine. Users may optionally supply a Google Gemini or Groq API key to enable LLM-augmented narrative synthesis, but this is not required and is not the default. This design prioritizes reproducibility. Users involved in systematic-review-grade work should retain AEE-only mode for retrieval and selection stages and consider LLM augmentation only for final narrative composition, if at all.

7. Future Directions

7.1 Planned evaluation studies

Three studies are planned to characterize AuditMed's real-world performance. Sample sizes are preliminary and will be refined with formal power analysis prior to enrollment; IRB approval will be sought for any study involving human participants prior to enrollment.

Study 1 — Retrieval breadth comparison. A set of fifty clinical drug-information questions will be answered using (a) AuditMed, (b) PubMed alone, and (c) Lexicomp. Source-retrieval sensitivity against a blinded reference answer and time-to-answer will be compared. The sample of fifty was chosen as a pragmatic minimum to support stratified analysis across a small number of question categories; this will be revised with formal power analysis.

Study 2 — Synthesis-quality assessment. Ten clinical questions will have responses generated by AuditMed in parallel with responses authored by experienced drug-information pharmacists. Two blinded independent reviewers will rate each response on a structured rubric (completeness, source fidelity, appropriate uncertainty framing, readability). Inter-rater agreement will be reported as Gwet's AC1 (which is preferred over Cohen's kappa for outcomes with imbalanced marginal distributions) with percent agreement as a secondary descriptor.

Study 3 — Educational efficacy pilot. Second-year PharmD students will be randomized to either standard drug-information-course instruction or standard instruction plus AuditMed-based laboratory exercises. The primary endpoint will be performance on a post-course evidence-appraisal examination; secondary endpoints will include student-reported self-efficacy and tool-use patterns during subsequent APPE rotations. IRB approval will be sought before enrollment.

7.2 Technical roadmap

- Correction of the two parser defects reported in Section 4.3 prior to any formal evaluation study.

- Expansion of the clinical-finding pattern library to cover hepatic, endocrine, pediatric, and geriatric-specific domains.

- Integration of NICE and SIGN guidelines and the WHO Essential Medicines List for broader international coverage.

- Localization into Spanish and French to support non-anglophone pharmacy education.

- Programmatic integration with institutional library-proxy servers so that full-text access can be routed through the user's institution when available.

- An offline mode that bundles a curated subset of DailyMed and LactMed data for settings without reliable internet connectivity.

- Expanded audit logging for educational settings, so instructors can review student workflow patterns in aggregate.

7.3 Governance and open development

AuditMed is currently developed and maintained by a single author. Sustained educational adoption will require a governance model that is not dependent on one individual.

8. Conclusion

AuditMed is a single-file, browser-based clinical evidence audit platform that integrates nineteen free public application programming interfaces into a six-stage Search–Select–Parse–Analyze–Infer–Create pipeline, supports patient-case ingestion with browser-local storage, and generates case-grounded Clinical Inference Documents that include confidence-tagged inferential findings and prioritized verification steps.

Preliminary stress-testing against eleven cases of the Complex Clinical Case Compendium Software Validation Suite demonstrated that the pipeline completes without fatal errors under extreme multi-morbidity, that quantitative-finding detection performs as designed for hematologic and cardiac-biomarker domains, and that two reproducible parser defects — an age-as-fever regex defect and a diagnosis-versus-medication parsing defect — are present in current outputs and will be addressed before formal evaluation. Evidence-linkage rate varied widely across cases and identifies the semantic-matching step as the principal near-term bottleneck.

AuditMed does not replace commercial clinical decision-support systems and has not yet undergone formal clinical-validity evaluation. Its value at the current stage is in providing a free, transparent, auditable workflow that educates trainees in the habits of multi-source synthesis, flags the limits of retrieved evidence honestly, and leaves final clinical judgment with the treating clinician. Formal evaluation studies are planned.

Invitations to collaborate on the planned evaluation studies or to test the platform in local educational contexts may be directed to the corresponding author.

Declarations

Ethics approval and consent to participate

Not applicable. The stress-test corpus used in this work consists of synthetic cases from the Complex Clinical Case Compendium Software Validation Suite, which is explicitly designated for software validation and contains no real patient data. No human participants were involved. Planned evaluation studies (Section 7.1) will be submitted for Institutional Review Board review prior to enrollment.

Consent for publication

Not applicable.

Data availability

All primary data supporting the findings of this study are contained within the manuscript itself. The eleven synthetic cases used as input are reproduced verbatim in Appendix A (source-case block preceding each machine-generated transcript), and the eleven Clinical Inference Reports generated by AuditMed are reproduced verbatim in Appendix A (machine-output block). No additional supplementary datasets are withheld.

Code availability

AuditMed is available for free public use at https://auditmed9.onrender.com/. The platform is open in the sense of open access and open use (free to run, no subscription required, no advertisements, no identifiable data collection beyond authentication). The underlying source code is not distributed under a conventional open-source license at this time and is not currently posted to a public code repository.

Competing interests

The author declares no financial conflicts of interest related to the platform. AuditMed has no commercial sponsorship, does not display third-party advertisements, and does not collect identifiable user data beyond that required for authentication.

Funding

No external funding was received for the development of AuditMed or for the preparation of this report.

Authors' contributions (CRediT)

David J. Ferguson is the sole author and is responsible for all CRediT roles: conceptualization, methodology, software design with AI-assistance, validation, formal analysis, investigation, resources, data curation, writing (original draft and review and editing), visualization, supervision, and project administration.

Acknowledgments

None.

Disclaimer

AuditMed is provided for research and educational purposes only. It is not a medical device, has not been evaluated by the United States Food and Drug Administration or any equivalent regulatory authority, and is not intended to diagnose, treat, cure, or prevent any disease. Users remain responsible for all clinical decisions and for compliance with their institutional privacy and professional-practice policies.

References

1. Berg C, Philipp R, Taff SD. Scoping review of critical thinking literature in healthcare education. Occup Ther Health Care. 2023;37(4):487–506. doi:10.1080/07380577.2021.1879419. PMID: 33571065.

2. Sullivan EA. Critical thinking in clinical nurse education: application of Paul's model of critical thinking. Nurse Educ Pract. 2012;12(6):322–327. doi:10.1016/j.nepr.2012.03.005. PMID: 22525600.

3. DeRuiter M, Ginsberg SM. Conscious clinical education: the Evidence-Based Education–Clinical Education model. Semin Speech Lang. 2020;41(4):320–331. doi:10.1055/s-0040-1713779. PMID: 32698224.

4. Okuda Y, Godwin SA, Jacobson L, Wang E. SimWars: bringing emergency medicine education to the next level. J Emerg Med. 2014;47(5):596–602. doi:10.1016/j.jemermed.2014.06.023. PMID: 25224173.

5. Kleinpell R, Ely EW, Williams G, Liolios A. Web-based resources for critical care education. Crit Care Med. 2011;39(3):541–553. doi:10.1097/CCM.0b013e318206b5b5. PMID: 21169819.

6. Billings DM. Argument mapping. J Contin Educ Nurs. 2008;39(6):246–247. doi:10.3928/00220124-20080601-09. PMID: 18557281.

7. Gazarian PK. Digital stories: incorporating narrative pedagogy. J Nurs Educ. 2010;49(5):287–290. doi:10.3928/01484834-20100115-07. PMID: 20143754.

8. Henderson JV. Comprehensive, technology-based clinical education: the "virtual practicum." Int J Psychiatry Med. 1998;28(1):41–79. doi:10.2190/NQEN-KRT8-19GA-R0BV. PMID: 9617648.

9. Schwartz H. Computer software for critical thinking. Comput Educ. 1988;12(1):209–214. doi:10.1016/0360-1315(88)90072-3.

10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD. PMID: 18436948.

11. U.S. Department of Health and Human Services, Office for Civil Rights. Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. Safe Harbor method (18 categories). Available at: https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html. Accessed 18 April 2026.

12. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372.

13. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625–632. doi:10.1007/s41999-023-00777-y.

14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.

15. National Library of Medicine. PubMed / MEDLINE. Available at: https://pubmed.ncbi.nlm.nih.gov/. Accessed 18 April 2026.

16. European Molecular Biology Laboratory–European Bioinformatics Institute. Europe PMC. Available at: https://europepmc.org/. Accessed 18 April 2026.

17. CrossRef. Available at: https://www.crossref.org/. Accessed 18 April 2026.

18. OurResearch. OpenAlex. Available at: https://openalex.org/. Accessed 18 April 2026.

19. Cochrane Library. John Wiley & Sons. Available at: https://www.cochranelibrary.com/. Accessed 18 April 2026.

20. Cold Spring Harbor Laboratory. medRxiv. Available at: https://www.medrxiv.org/. Accessed 18 April 2026.

21. Cold Spring Harbor Laboratory. bioRxiv. Available at: https://www.biorxiv.org/. Accessed 18 April 2026.

22. World Health Organization. Institutional Repository for Information Sharing (IRIS). Available at: https://iris.who.int/. Accessed 18 April 2026.

23. OurResearch. Unpaywall. Available at: https://unpaywall.org/. Accessed 18 April 2026.

24. National Library of Medicine. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/. Accessed 18 April 2026.

25. U.S. Food and Drug Administration. openFDA. Available at: https://open.fda.gov/. Accessed 18 April 2026.

26. National Library of Medicine. DailyMed. Available at: https://dailymed.nlm.nih.gov/. Accessed 18 April 2026.

27. National Library of Medicine. Drugs and Lactation Database (LactMed). NCBI Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK501922/. Accessed 18 April 2026.

28. National Library of Medicine. MedlinePlus. Available at: https://medlineplus.gov/. Accessed 18 April 2026.

29. National Library of Medicine. RxNorm and RxClass. Available at: https://www.nlm.nih.gov/research/umls/rxnorm/. Accessed 18 April 2026.

30. American Society of Health-System Pharmacists. AHFS Drug Information. Available at: https://www.ashp.org/products-and-services/ahfs-drug-information. Accessed 18 April 2026. (Referenced via RxClass therapeutic classifications; AuditMed does not query AHFS content directly.)

31. Wishart DS, et al. DrugBank. University of Alberta. Available at: https://go.drugbank.com/. Accessed 18 April 2026.

32. European Bioinformatics Institute. UniChem. Available at: https://www.ebi.ac.uk/unichem/. Accessed 18 April 2026.

33. Drugs.com. Available at: https://www.drugs.com/. Accessed 18 April 2026. (Integrated as direct-linked reference only; not an API source.)

34. Wolters Kluwer. Lexi-Interact (Lexicomp). Available at: https://www.wolterskluwer.com/en/solutions/lexicomp. Accessed 18 April 2026. (Integrated as direct-linked reference only; not an API source.)

35. GlobalRPh. Available at: https://globalrph.com/. Accessed 18 April 2026. (Integrated as direct-linked reference only; not an API source.)

36. Ferguson DJ. Complex Clinical Case Compendium Software Validation Suite (v1.0). 40-case synthetic corpus for software validation. April 2026. For software validation purposes only; not for clinical decision-making. Cases 30–40 reproduced verbatim in Appendix A of this manuscript.

37. Wolters Kluwer. UpToDate. Available at: https://www.uptodate.com/. Accessed 18 April 2026.

38. Merative. Micromedex. Available at: https://www.merative.com/clinical-decision-support. Accessed 18 April 2026.

39. EBSCO Information Services. DynaMed. Available at: https://www.dynamed.com/. Accessed 18 April 2026.

40. Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia. Available at: https://www.covidence.org/. Accessed 18 April 2026.

41. Rayyan Systems, Inc. Rayyan. Available at: https://www.rayyan.ai/. Accessed 18 April 2026.

42. National Institute for Health and Care Research, Centre for Reviews and Dissemination, University of York. PROSPERO: International Prospective Register of Systematic Reviews. Available at: https://www.crd.york.ac.uk/prospero/. Accessed 18 April 2026.

43. National Institute for Health and Care Excellence (NICE). Available at: https://www.nice.org.uk/. Accessed 18 April 2026.

44. Scottish Intercollegiate Guidelines Network (SIGN). Available at: https://www.sign.ac.uk/. Accessed 18 April 2026.

45. World Health Organization. Model List of Essential Medicines. Available at: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02. Accessed 18 April 2026.

Appendix A. Case-Level Stress-Test Transcripts (Cases 30–40)

This appendix reproduces the eleven synthetic source-case descriptions (drawn verbatim from Cases 30 through 40 of the Complex Clinical Case Compendium Software Validation Suite [36]) and the corresponding verbatim, unedited Clinical Inference Report outputs generated by AuditMed for each case. Each subsection is headed by the case number and a short clinical descriptor. The source-case block precedes the machine-generated transcript. Apparent parsing artefacts (for example, patient age being reported as a body temperature, or medication strings appearing in the diagnoses list) are retained as they appeared at the time of testing and are discussed quantitatively in Section 4.3 and summarized in Table 1.

A.1. Case 30 — Gastroparesis with Intestinal Failure, TPN-Associated Liver Disease, and Concurrent Acute Intermittent Porphyria

Source case (verbatim)

Patient: 36 y/o F, BMI 15.8, Caucasian | Disciplines: GI, Hepatology, Surgery, Nutrition, Hematology, Pain Mgmt, Psychiatry, Vascular Surgery, ID, Endocrinology, Pharmacy

Active Disease States (20+)

Severe diabetic gastroparesis (T1DM x22 yr); CIPO; intestinal failure (TPN x4 yr); IFALD (F3-4); CLABSI x8 (MRSA, Candida); SVC syndrome (all upper central veins occluded); limited access (only L femoral Hickman); AIP (concurrent); SIBO; D-lactic acidosis; recurrent C. diff; short bowel (80 cm post-adhesiolysis); T1DM with autonomic neuropathy; retinopathy; nephropathy (CKD 3b); peripheral neuropathy; depression; chronic pain; malnutrition (albumin 1.6); trace element deficiencies; metabolic bone disease; EFA deficiency; recurrent VTE

Clinical Presentation

Rigors, 39.8 C, hypotension — 9th CLABSI (VRE from L femoral Hickman, her ONLY remaining line). Progressive jaundice (Tbili 12.4, IFALD). Venography: bilateral SVC, bilateral subclavian, R IJ all occluded. Only access L femoral (infected) +/- hepatic vein/translumbar IVC. Severe abdominal pain (porphyria attack triggered by infection, PBG 68). Completely TPN-dependent (zero enteral tolerance).

Key Laboratory / Imaging Data

Blood cx VRE (E. faecium), Tbili 12.4, AST 120, ALT 98, ALP 340, albumin 1.6, INR 1.8, ammonia 62, Cr 2.4, Na 128, K 3.2, Mg 0.8, Zn 28 (low), Cu 52 (low), Se 42 (low), Mn 18 (elevated — neurotoxicity risk), urine PBG 68, HbA1c 10.4%, prealbumin 4, venography: all upper veins occluded

Current Medications

TPN (intralipid reduced, Mn removed, carnitine added), IV daptomycin 8 mg/kg, ethanol lock therapy, IV hemin x4d (porphyria), IV D10%, IV morphine PCA, ondansetron, insulin pump, octreotide 50 SQ TID, ursodiol 300 TID, trace elements (Zn/Cu/Se supplemented)

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:50:57.793Z
Files: Library case #30
Cases: 1

```
==============================
CASE 1: 30
==============================
```

Type: CASE 30
File: Library case #30 (pp. 31-31)
Demographics: 36
Diagnoses: D10 [D10], CKD, neuropathy, depression, ALL, chronic pain, diabetes mellitus, type 1 diabetes, chronic kidney disease, gastrointestinal

REASONING CHAIN:
1. Case profile: 36 patient with working diagnoses of D10 [D10], CKD, neuropathy - 12 lab value(s), 6 medication(s) documented
2. Case-derived findings: 1 pattern identified (1 moderate/mild)
3. Evidence base: spans 1910-2024; 0 distinct methodology type(s) - 0 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 1 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Hyponatremia (Na 128 mEq/L) [LIMITED CONFIDENCE]
    -> Evaluate volume status (SIADH vs hypovolemic vs hypervolemic); medication review
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:
1. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
    Rationale: Hyponatremia (Na 128 mEq/L)
    Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
2. [ROUTINE] Comprehensive medication reconciliation and interaction review for 6 agents
    Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review
    Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria
3. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application
    Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician
    Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:
- Retrieved evidence does not contain explicit recommendation-style statements. Proceed with established standard-of-care for D10 [D10], CKD, neuropathy, depression, ALL, chronic pain, diabetes mellitus, type 1 diabetes, chronic kidney disease, gastrointestinal while consulting specialty-specific guidelines (IDSA, ACC/AHA, ADA, KDIGO, or others as applicable). [LIMITED]
- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (7 source(s) retrieved - 1 limited-confidence finding(s) flagged for verification)

A.2. Case 31 — Multisystem Sarcoidosis with Complete Heart Block, Neurosarcoidosis, and Hypercalcemic Crisis

Source case (verbatim)

Patient: 48 y/o F, BMI 32.0, African American | Disciplines: Pulmonology, Cardiology, Neurology, Nephrology, Endocrinology, Ophthalmology, Dermatology, Rheumatology, Pharmacy

Active Disease States (20+)

Sarcoidosis (multisystem); cardiac sarcoid (CHB requiring temp pacing, EF 32%); neurosarcoid (bilateral CN VII palsy, hypothalamic DI); pulmonary sarcoid (stage III, FVC 58%); hypercalcemia (Ca 13.2); nephrocalcinosis with CKD 3; hepatic sarcoid; splenic sarcoid; posterior uveitis; erythema nodosum; lupus pernio; SFN; depression; arthritis; hypogammaglobulinemia; secondary AI; DI; steroid-induced DM; osteoporosis; obesity

Clinical Presentation

Syncope. ECG: CHB with ventricular escape 28 bpm. Temp wire placed. Echo: basal septal thinning, EF 32%, wall motion abnormalities NOT in coronary distribution. FDG-PET (72h high-fat/low-carb prep): intense focal/patchy FDG in basal septum + LV wall. Bilateral CN VII palsy (new). MRI brain: enhancing hypothalamic lesion, absent posterior pituitary bright spot. Ca 13.2, PTH suppressed, 1,25-(OH)2D elevated.

Key Laboratory / Imaging Data

Ca 13.2, PTH 8 (suppressed), 1,25-(OH)2D 86 (elevated), 25-OH-D 18, Cr 2.2, ACE 128, FDG-PET cardiac+, EF 32%, FVC 58%, bilateral CN VII palsy, urine osm 120 (DI), cortisol AM 4.8, IgG 480 (low), Hgb 10.4, glucose 248

Current Medications

Temp pacing wire, IV methylpred 1 g x3d then oral pred 40 mg, IV NS + zoledronic acid (Ca crisis but CKD3 concern), infliximab or MTX (steroid-sparing), desmopressin (DI), hydrocortisone stress dosing, insulin, CPAP

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:49:06.025Z
Files: Library case #31
Cases: 1

===========================
CASE 1: 31
===========================

Type: CASE 31
File: Library case #31 (pp. 32-32)
Demographics: 48
Diagnoses: heart block, CKD, depression, lupus, osteoporosis, hypercalcemia, obesity, diabetes mellitus, chronic kidney disease

REASONING CHAIN:
1. Case profile: 48 patient with working diagnoses of heart block, CKD, depression - 3 lab value(s), 4 medication(s) documented
2. Case-derived findings: 1 pattern identified (1 moderate/mild)
3. Evidence base: spans 1947-2025; 1 distinct methodology type(s) - 0 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required

5. 1 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.

6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:

- Fever (48 C) [LIMITED CONFIDENCE]

  -> Infection workup — blood cultures, imaging, source identification

  ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:

1. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

  Rationale: Fever (48 C)

  Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

2. [ROUTINE] Comprehensive medication reconciliation and interaction review for 4 agents

  Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review

  Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

3. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application

  Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician

  Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Retrieved evidence does not contain explicit recommendation-style statements. Proceed with established standard-of-care for heart block, CKD, depression, lupus, osteoporosis, hypercalcemia, obesity, diabetes mellitus, chronic kidney disease while consulting specialty-specific guidelines (IDSA, ACC/AHA, ADA, KDIGO, or others as applicable). [LIMITED]

- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (10 source(s) retrieved - 1 limited-confidence finding(s) flagged for verification)

A.3. Case 32 — POEMS Syndrome with Castleman Disease, Severe Pulmonary Hypertension, and Progressive Neuropathy

Source case (verbatim)

Patient: 54 y/o M, BMI 28.6, Japanese descent | Disciplines: Hematology/Oncology, Neurology, Cardiology, Pulmonology, Nephrology, Endocrinology, Dermatology, Ophthalmology, Pharmacy

Active Disease States (20+)

POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes); osteosclerotic myeloma (lambda); Castleman disease (multicentric); pulmonary HTN (severe, mean PAP 52); progressive demyelinating polyneuropathy (wheelchair-dependent); papilledema; endocrinopathies (AI, hypothyroidism, hypogonadism, DM); hepatosplenomegaly; ascites + pleural effusions; skin changes (hyperpigmentation, hemangiomas, hypertrichosis, white nails); thrombocytosis (Plt 680K); polycythemia; CRI; depression; chronic fatigue; clubbing; Raynaud; arthralgias

Clinical Presentation

Progressive bilateral foot drop x4 mo, now wheelchair-bound. NCS: severe demyelinating polyneuropathy. SPEP: IgG lambda M-protein 1.2 g/dL. Skeletal survey: osteosclerotic R iliac lesion. PET: FDG-avid iliac lesion +

lymphadenopathy. Echo: RVSP 52, R heart strain. Hyperpigmentation, hemangiomas, gynecomastia, bilateral edema, bilateral pleural effusions, ascites. Papilledema.

Key Laboratory / Imaging Data

SPEP M-spike IgG lambda 1.2, VEGF 2400 (markedly elevated), IL-6 elevated, skeletal survey: osteosclerotic lesion, PET FDG-avid, NCS: severe demyelinating, mean PAP 52, RVSP 52, EF 55% but RV strain, cortisol 3.8, TSH 18, testosterone 68, glucose 210, Plt 680K, Hgb 18.2, Cr 1.8, albumin 2.4

Current Medications

Radiation to solitary osteosclerotic lesion (primary Rx if solitary), lenalidomide + dexamethasone (if disseminated considering), diuretics for effusions, sildenafil (PAH), hormone replacement (cortisol, thyroid, testosterone), gabapentin (neuropathic pain), insulin, therapeutic thoracentesis/paracentesis

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:47:53.707Z
Files: Library case #32
Cases: 1

===========================
CASE 1: 32
===========================

Type: CASE 32
File: Library case #32 (pp. 33-33)
Demographics: 54
Diagnoses: neuropathy, depression, hypothyroidism, hypertension, diabetes mellitus

REASONING CHAIN:
1. Case profile: 54 patient with working diagnoses of neuropathy, depression, hypothyroidism - 6 lab value(s), 2 medication(s) documented
2. Case-derived findings: 1 pattern identified (1 moderate/mild)
3. Evidence base: spans 1983-2025; 1 distinct methodology type(s) - 7 evidence-linked statement(s) extracted
4. 1 case finding(s) cross-referenced to retrieved evidence with traceable supporting statements
5. 1 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: partial evidence support; selective verification of unmatched findings needed

INFERENTIAL FINDINGS:
- Fever (54 C) [LIMITED CONFIDENCE]
   -> Infection workup — blood cultures, imaging, source identification
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Working diagnosis: hypothyroidism [LIMITED CONFIDENCE]
   -> Evidence base addresses this condition directly
   [6] Hypothyroidism is one of the late side effects of radiation to the neck.
   [6] The main aim of the study was to assess the incidence of primary hypothyroidism in patients with head and neck cancers, who received therapeutic external beam radiation; to evaluate the time duration ...
   [5] Despite treatment with levothyroxine, hypothyroidism and autoimmune thyroiditis (AIT) may be associated with reduced quality of life (QoL), an enigmatic condition referred to as "syndrome T".

RECOMMENDED VERIFICATION STEPS:

1. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Fever (54 C)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

2. [ROUTINE] Strengthen evidence base for working diagnosis: hypothyroidism — retrieved sources are of limited individual strength

   Rationale: Confidence in inference is limited by source quality or specificity

   Resources: PubMed with MeSH-specific search, Cochrane Library for systematic reviews, Clinical practice guidelines from relevant specialty society

3. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application

   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician

   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Retrieved evidence does not contain explicit recommendation-style statements. Proceed with established standard-of-care for neuropathy, depression, hypothyroidism, hypertension, diabetes mellitus while consulting specialty-specific guidelines (IDSA, ACC/AHA, ADA, KDIGO, or others as applicable). [LIMITED]
- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (12 source(s) retrieved - 2 limited-confidence finding(s) flagged for verification)

A.4. Case 33 — Immune-Checkpoint-Inhibitor Triple Toxicity — Myocarditis, Myositis, and Myasthenic Crisis

Source case (verbatim)

Patient: 68 y/o M, BMI 27.4, Caucasian, on pembrolizumab for melanoma | Disciplines: Oncology, Cardiology, Neurology, Rheumatology, CC, Pulmonology, Endocrinology, GI, Dermatology, Pharmacy

Active Disease States (20+)

ICI toxicity: myocarditis (troponin 18.4, EF 25%, CHB), myositis (CK 12K), myasthenic crisis (FVC 0.9L, intubated) — "triple M syndrome"; melanoma stage IV (brain mets x2, prior ICI response); ICI-induced AI; hypothyroidism; hepatitis (ALT 380); colitis; T1DM (DKA); nephritis (Cr 2.8); SJS-like dermatitis; COPD; chronic pain; depression

Clinical Presentation

On pembrolizumab x8 months with tumor response. Develops acute dyspnea, chest pain, proximal weakness (cannot lift head off pillow), diplopia, and ptosis over 5 days. Troponin 18.4, EF 25%, CHB on telemetry. CK 12K. FVC 0.9L -> intubated. Cardiac MRI: diffuse edema + subepicardial LGE. Anti-striational Ab+, anti-AChR Ab+. Simultaneously: DKA (glucose 520, pH 7.18), bloody diarrhea, blistering rash, ALT 380, Cr 2.8.

Key Laboratory / Imaging Data

Troponin 18.4, BNP 12K, EF 25%, CHB, CK 12K, anti-AChR Ab+, anti-striational Ab+, FVC 0.9L, glucose 520, pH 7.18, ALT 380, Cr 2.8, cortisol 2.1, TSH 38, skin bx: SJS-like, colonoscopy: severe colitis

Current Medications

Pembrolizumab PERMANENTLY DISCONTINUED, IV methylpred 1 g x5d, IVIG 2 g/kg x5d (myocarditis + MG), PLEX (MG crisis), pyridostigmine (cautious — can worsen cardiac conduction), temp pacing, insulin drip (DKA), IV hydrocortisone (AI), levothyroxine, wound care (SJS-like dermatitis)

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:46:50.040Z
Files: Library case #33
Cases: 1

============================
CASE 1: 33
============================

Type: CASE 33
File: Library case #33 (pp. 34-34)
Demographics: 68
Diagnoses: COPD, depression, ALL, hypothyroidism, DKA, melanoma, chronic pain, diabetes mellitus, type 1 diabetes, gastrointestinal, diabetic ketoacidosis

REASONING CHAIN:
1. Case profile: 68 patient with working diagnoses of COPD, depression, ALL - 6 lab value(s), 4 medication(s) documented
2. Case-derived findings: 2 patterns identified (1 critical, 1 moderate/mild)
3. Evidence base: spans 2005-2025; 3 distinct methodology type(s) - 11 evidence-linked statement(s) extracted
4. 2 case finding(s) cross-referenced to retrieved evidence with traceable supporting statements
5. 2 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: partial evidence support; selective verification of unmatched findings needed

INFERENTIAL FINDINGS:
- Elevated troponin (18.4 ng/mL) [LIMITED CONFIDENCE]
   -> Myocardial injury — rule out ACS; serial troponins and ECG indicated
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Fever (68 C) [LIMITED CONFIDENCE]
   -> Infection workup — blood cultures, imaging, source identification
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Working diagnosis: copd [HIGH CONFIDENCE]
   -> Evidence base addresses this condition directly
   [4] Mind-body exercise has been generally recognized as a beneficial strategy to improve mental health in those with Chronic Obstructive Pulmonary Disease (COPD).
   [4] The aim of the present study was to systematically analyze the effects of mind-body exercise for COPD patients with anxiety and depression and provide scientific evidence-based exercise prescription.
   [2] Chronic obstructive pulmonary disease (COPD) contributes considerably to morbidity and mortality worldwide, necessitating innovative interventions to enhance patient outcomes.
- Working diagnosis: depression [HIGH CONFIDENCE]
   -> Evidence base addresses this condition directly
   [4] The aim of the present study was to systematically analyze the effects of mind-body exercise for COPD patients with anxiety and depression and provide scientific evidence-based exercise prescription.

[1] Depression associated with Chronic Obstructive Pulmonary Disease (COPD) is a detrimental complication that significantly impairs patients' quality of life.

[1] This study aims to develop an online predictive model to estimate the risk of depression in COPD patients.

RECOMMENDED VERIFICATION STEPS:

1. [IMMEDIATE] Serial cardiac enzymes, 12-lead ECG, and consider echocardiography
   Rationale: Elevated troponin (18.4 ng/mL): Myocardial injury — rule out ACS; serial troponins and ECG indicated
   Resources: ACC/AHA ACS guidelines, TIMI/GRACE risk calculators
2. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
   Rationale: Elevated troponin (18.4 ng/mL)
   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
3. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
   Rationale: Fever (68 C)
   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
4. [ROUTINE] Comprehensive medication reconciliation and interaction review for 4 agents
   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review
   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria
5. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application
   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician
   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Address Elevated troponin (18.4 ng/mL) — Myocardial injury — rule out ACS; serial troponins and ECG indicated [Case-derived] [HIGH]
- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: MODERATE (12 source(s) retrieved - 3 systematic review/meta-analysis - 1 RCT(s) - 2 high-confidence inference(s) - 2 limited-confidence finding(s) flagged for verification)

A.5. Case 34 — Catastrophic EGPA (Churg-Strauss) with Eosinophilic Myocarditis and Status Asthmaticus

Source case (verbatim)

Patient: 41 y/o F, BMI 26.8, Caucasian | Disciplines: Pulmonology, Cardiology, Rheumatology, CC, Neurology, ENT, Dermatology, Nephrology, Hematology, Pharmacy

Active Disease States (20+)

EGPA (Churg-Strauss); catastrophic cardiac variant (eosinophilic myocarditis, EF 18%, VT); status asthmaticus (intubated); eosinophilia 28K; mononeuritis multiplex (bilateral foot drop, L wrist drop); migratory pulmonary infiltrates; chronic sinusitis with polyposis; GI eosinophilic gastroenteritis; palpable purpura + subcutaneous nodules; coronary vasculitis (troponin 6.4); pericardial effusion; renal involvement (MPO-ANCA+, Cr 2.4); DVT; endomyocardial fibrosis developing; depression; steroid-dependent asthma (20+ yr); osteoporosis; AI

Clinical Presentation

20-year asthma history. Acute chest pain, dyspnea, bilateral foot/wrist drop x1 wk. Troponin 6.4. Echo: EF 18%, global hypokinesis, apical thrombus. Eosinophilia 28K. Cardiac MRI: diffuse myocardial edema, subepicardial LGE

(eosinophilic myocarditis). EMB: eosinophilic infiltration + necrosis. Severe asthma exacerbation requiring ventilation. Purpura on legs. MPO-ANCA+. Cr 2.4 with RBC casts.

Key Laboratory / Imaging Data

Eos 28K, troponin 6.4, BNP 8400, EF 18%, cardiac MRI: diffuse edema + subepicardial LGE, EMB: eosinophilic infiltration, MPO-ANCA+, Cr 2.4, UA RBC casts, CXR migratory infiltrates, IgE 1800, NCS: mononeuritis multiplex, Plt 340K, ESR 96

Current Medications

IV methylpred 1 g x3d -> pred 1 mg/kg, IV CYC (pulse), mepolizumab (anti-IL-5 planned for maintenance), mechanical ventilation, anticoagulation for LV thrombus (but Plt management), temp pacing (backup for VT), amiodarone, diuretics, insulin

Machine-generated Clinical Inference Report (verbatim)
=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:45:59.223Z
Files: Library case #34
Cases: 1

==============================
CASE 1: 34
==============================

Type: CASE 34
File: Library case #34 (pp. 35-35)
Demographics: 41
Diagnoses: DVT, asthma, depression, vasculitis, osteoporosis, deep vein thrombosis, gastrointestinal

REASONING CHAIN:
1. Case profile: 41 patient with working diagnoses of DVT, asthma, depression - 4 lab value(s), 5 medication(s) documented
2. Case-derived findings: 3 patterns identified (1 critical, 1 high-severity, 1 moderate/mild)
3. Evidence base: spans 2004-2026; 1 distinct methodology type(s) - 1 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 3 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Elevated troponin (6.4 ng/mL) [LIMITED CONFIDENCE]
   -> Myocardial injury — rule out ACS; serial troponins and ECG indicated
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Elevated BNP (8400 pg/mL) [LIMITED CONFIDENCE]
   -> Suggests volume overload / heart failure; echo review recommended
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Fever (41 C) [LIMITED CONFIDENCE]
   -> Infection workup — blood cultures, imaging, source identification
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:

1. [IMMEDIATE] Serial cardiac enzymes, 12-lead ECG, and consider echocardiography

   Rationale: Elevated troponin (6.4 ng/mL): Myocardial injury — rule out ACS; serial troponins and ECG indicated

   Resources: ACC/AHA ACS guidelines, TIMI/GRACE risk calculators

2. [URGENT] Serial cardiac enzymes, 12-lead ECG, and consider echocardiography

   Rationale: Elevated BNP (8400 pg/mL): Suggests volume overload / heart failure; echo review recommended

   Resources: ACC/AHA ACS guidelines, TIMI/GRACE risk calculators

3. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Elevated troponin (6.4 ng/mL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

4. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Elevated BNP (8400 pg/mL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

5. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Fever (41 C)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

6. [ROUTINE] Comprehensive medication reconciliation and interaction review for 5 agents

   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review

   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

7. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application

   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician

   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Address Elevated troponin (6.4 ng/mL) — Myocardial injury — rule out ACS; serial troponins and ECG indicated [Case-derived] [HIGH]

- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (9 source(s) retrieved - 1 systematic review/meta-analysis - 3 limited-confidence finding(s) flagged for verification)

A.6. Case 35 — PNH with Budd-Chiari, Aplastic-Anemia Overlap, and Breakthrough Meningococcal Sepsis on Eculizumab

Source case (verbatim)

Patient: 33 y/o M, BMI 22.4, African American | Disciplines: Hematology, Hepatology, ID, CC, Nephrology, GI, Pharmacy

Active Disease States (20+)

PNH (GPI-AP deficiency >90%); Budd-Chiari (hepatic vein thrombosis); aplastic anemia overlap; on eculizumab; breakthrough meningococcal sepsis (serogroup B despite vaccination); pancytopenia (Hgb 5.8, WBC 1.2, Plt 18K); hemolytic crisis (LDH 4200); portal HTN with varices; hepatic failure; recurrent thrombosis (DVT, splenic vein, portal vein); CKD 3; iron overload; chronic pain; depression; hemoglobinuria; BM failure; C3-mediated extravascular hemolysis on eculizumab

Clinical Presentation

On chronic eculizumab. Acute fever 40.8 C, neck stiffness, petechiae, hemodynamic collapse. Blood cx + CSF: N. meningitidis serogroup B (breakthrough). Concurrent hemolytic crisis (LDH 4200, Hgb 5.8, dark urine). Liver worsening (Budd-Chiari — ALT 480, Tbili 8.6, new ascites). Plt 18K. On warfarin (INR 2.8) but bleeding from gingiva and petechiae.

Key Laboratory / Imaging Data

Hgb 5.8, WBC 1.2, Plt 18K, LDH 4200, haptoglobin <10, INR 2.8 (warfarin), ALT 480, Tbili 8.6, Cr 2.1, flow: >90% GPI-AP deficient granulocytes, CSF: N. meningitidis, reticulocyte 14%, ferritin 3200, ascites new

Current Medications

Eculizumab 900 q2wk (continue through sepsis — complement blockade doesn't worsen meningococcal Rx), IV ceftriaxone (meningococcal), aggressive supportive care, pRBC/Plt transfusions, warfarin (held — active bleeding), IV vitamin K

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:43:18.589Z
Files: Library case #35
Cases: 1

============================
CASE 1: 35
============================

Type: CASE 35
File: Library case #35 (pp. 36-36)
Demographics: 33
Diagnoses: DVT, CKD, depression, anemia, sepsis, chronic pain, hypertension, chronic kidney disease, deep vein thrombosis, gastrointestinal

REASONING CHAIN:
1. Case profile: 33 patient with working diagnoses of DVT, CKD, depression - 7 lab value(s), 3 medication(s) documented
2. Case-derived findings: 2 patterns identified (1 critical, 1 high-severity, 0 moderate/mild)
3. Evidence base: spans 2012-2023; 0 distinct methodology type(s) - 0 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 2 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Severe anemia (Hgb 5.8 g/dL) [LIMITED CONFIDENCE]
    -> Transfusion threshold met in most settings; source evaluation needed
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Severe thrombocytopenia (Plt 18 K/uL) [LIMITED CONFIDENCE]
    -> Bleeding risk; consider HIT if on heparin, medication-induced, hematologic process
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:

1. [IMMEDIATE] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)

 Rationale: Severe anemia (Hgb 5.8 g/dL): Transfusion threshold met in most settings; source evaluation needed

 Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure

2. [URGENT] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)

 Rationale: Severe thrombocytopenia (Plt 18 K/uL): Bleeding risk; consider HIT if on heparin, medication-induced, hematologic process

 Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure

3. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

 Rationale: Severe anemia (Hgb 5.8 g/dL)

 Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

4. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

 Rationale: Severe thrombocytopenia (Plt 18 K/uL)

 Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

5. [ROUTINE] Comprehensive medication reconciliation and interaction review for 3 agents

 Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review

 Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

6. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application

 Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician

 Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Address Severe anemia (Hgb 5.8 g/dL) — Transfusion threshold met in most settings; source evaluation needed [Case-derived] [HIGH]

- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (9 source(s) retrieved - 2 limited-confidence finding(s) flagged for verification)

A.7. Case 36 — Severe Aplastic Anemia with PNH Clone in a Patient Declining Transfusion

Source case (verbatim)

Patient: 20 y/o F, BMI 19.6, Caucasian, Jehovah's Witness | Disciplines: Hematology, Ethics, CC, Nephrology, ID, Transfusion Medicine, Gynecology, Psychiatry, Pharmacy

Active Disease States (20+)

SAA (very severe, ANC <200); PNH clone (22%); Jehovah's Witness (refuses ALL blood products); Hgb 4.2 without transfusion option; neutropenic fever with Pseudomonas bacteremia; invasive pulmonary aspergillosis; cardiac decompensation (EF 30%, high-output failure from anemia); epistaxis; GI bleeding (Plt 4K); IDA; menorrhagia; AKI (prerenal); B12 deficiency; depression; chronic fatigue; hepatitis-associated AA

Clinical Presentation

Known SAA (ANC 180, Hgb 4.2, Plt 4K). High fevers, rigors, cough. Blood cx: Pseudomonas. CT chest: RUL halo sign (IPA, galactomannan 3.8). Adamantly refuses ALL blood products. HR 142, dyspnea at rest, EF 30% (high-output). Epistaxis. Continuous menorrhagia. Cr rising (prerenal from poor CO).

Key Laboratory / Imaging Data

ANC 180, Hgb 4.2, Plt 4K, retic 0.2%, blood cx Pseudomonas, galactomannan 3.8, Cr 1.8, BNP 4200, EF 30%, ferritin 4, B12 120, LDH 180, PNH clone 22% on flow

Current Medications

IV meropenem + tobramycin (Pseudomonas), liposomal amphotericin B (IPA), eltrombopag 150 mg daily (TPO agonist — SAA indication), horse ATG + cyclosporine (SAA first-line initiated), G-CSF, EPO 40K SQ TIW + iron IV sucrose (stimulate erythropoiesis), aminocaproic acid (antifibrinolytic), combined OCP (menorrhagia if accepted by patient), high-dose medroxyprogesterone, nasal packing, strict infection precautions

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:41:54.191Z
Files: Library case #36
Cases: 1

===========================

CASE 1: 36
===========================

Type: CASE 36
File: Library case #36 (pp. 37-37)
Demographics: 20
Diagnoses: deficiency [B12], B12 [B12], AKI, depression, anemia, B12 deficiency, ALL, bacteremia, aspergillosis, acute kidney injury, gastrointestinal, acute lymphoblastic leukemia

REASONING CHAIN:
1. Case profile: 20 patient with working diagnoses of deficiency [B12], B12 [B12], AKI - 5 lab value(s), 5 medication(s) documented
2. Case-derived findings: 3 patterns identified (1 critical, 2 high-severity, 0 moderate/mild)
3. Evidence base: spans 1978-2025; 0 distinct methodology type(s) - 0 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 3 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Elevated BNP (4200 pg/mL) [LIMITED CONFIDENCE]
    -> Suggests volume overload / heart failure; echo review recommended
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Severe anemia (Hgb 4.2 g/dL) [LIMITED CONFIDENCE]
    -> Transfusion threshold met in most settings; source evaluation needed
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Severe thrombocytopenia (Plt 4 K/uL) [LIMITED CONFIDENCE]
    -> Bleeding risk; consider HIT if on heparin, medication-induced, hematologic process
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:

1. [URGENT] Serial cardiac enzymes, 12-lead ECG, and consider echocardiography

   Rationale: Elevated BNP (4200 pg/mL): Suggests volume overload / heart failure; echo review recommended

   Resources: ACC/AHA ACS guidelines, TIMI/GRACE risk calculators

2. [IMMEDIATE] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)

   Rationale: Severe anemia (Hgb 4.2 g/dL): Transfusion threshold met in most settings; source evaluation needed

   Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure

3. [URGENT] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)

   Rationale: Severe thrombocytopenia (Plt 4 K/uL): Bleeding risk; consider HIT if on heparin, medication-induced, hematologic process

   Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure

4. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Elevated BNP (4200 pg/mL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

5. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Severe anemia (Hgb 4.2 g/dL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

6. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Severe thrombocytopenia (Plt 4 K/uL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

7. [ROUTINE] Comprehensive medication reconciliation and interaction review for 5 agents

   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review

   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

8. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application

   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician

   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Address Severe anemia (Hgb 4.2 g/dL) — Transfusion threshold met in most settings; source evaluation needed [Case-derived] [HIGH]

- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (11 source(s) retrieved - 3 limited-confidence finding(s) flagged for verification)

A.8. Case 37 — IgG4-Related Disease Mimicking Cholangiocarcinoma with Multi-Organ Infiltration

Source case (verbatim)

Patient: 63 y/o M, BMI 28.4, Japanese descent | Disciplines: Rheumatology, GI, Hepatology, Urology, Ophthalmology, Pulmonology, Nephrology, Pathology, Surgery, Pharmacy

Active Disease States (20+)

IgG4-RD; AIP type 1 ("sausage-shaped" pancreas); retroperitoneal fibrosis with bilateral ureteral obstruction; bilateral orbital pseudotumor; IgG4-sclerosing cholangitis mimicking CCA; sialadenitis (bilateral parotid); IgG4-TIN (Cr 2.8); aortitis (infrarenal); pachymeningitis (headaches, CN palsies); thyroiditis (hypothyroidism);

exocrine insufficiency; new-onset DM (type 3c); depression; weight loss; anemia; hypoalbuminemia; recurrent cholangitis; lymphadenopathy

Clinical Presentation

Painless jaundice, weight loss 15 kg, bilateral orbital swelling. MRCP: diffuse pancreatic enlargement with capsule-like rim + biliary irregularity mimicking CCA. CA 19-9: 280. IgG4: 820. CT: retroperitoneal tissue encasing ureters (hydronephrosis), infrarenal aortic wall thickening. Bilateral orbital masses. New DM. Cr 2.8 (TIN). Being worked up for CCA — distinction is CRITICAL before surgery.

Key Laboratory / Imaging Data

IgG4 820, total IgG 2800, CA 19-9 280, IgG4/IgG ratio >40%, biopsy: storiform fibrosis + >50 IgG4+ cells/HPF + obliterative phlebitis, Cr 2.8, glucose 240, HbA1c 8.4%, Tbili 12, ALP 480, GGT 320, lipase 42, CT: "sausage pancreas," RP fibrosis, orbital masses, aortitis

Current Medications

Prednisone 40 mg daily (dramatic response expected in IgG4-RD), rituximab (steroid-sparing, planned), bilateral ureteral stents, PERT, insulin, levothyroxine, ursodiol, biliary stent (ERCP)

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:40:27.157Z
Files: Library case #37
Cases: 1

===========================

CASE 1: 37
===========================

Type: CASE 37
File: Library case #37 (pp. 38-38)
Demographics: 63
Diagnoses: pancreatitis, depression, anemia, hypothyroidism, diabetes mellitus, gastrointestinal

REASONING CHAIN:
1. Case profile: 63 patient with working diagnoses of pancreatitis, depression, anemia - 6 lab value(s), 3 medication(s) documented
2. Case-derived findings: 1 pattern identified (1 moderate/mild)
3. Evidence base: spans 1978-2025; 0 distinct methodology type(s) - 1 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 1 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Fever (63 C) [LIMITED CONFIDENCE]
    -> Infection workup — blood cultures, imaging, source identification
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:

1. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Fever (63 C)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

2. [ROUTINE] Comprehensive medication reconciliation and interaction review for 3 agents

   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review

   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

3. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application

   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician

   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Retrieved evidence does not contain explicit recommendation-style statements. Proceed with established standard-of-care for pancreatitis, depression, anemia, hypothyroidism, diabetes mellitus, gastrointestinal while consulting specialty-specific guidelines (IDSA, ACC/AHA, ADA, KDIGO, or others as applicable). [LIMITED]

- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (12 source(s) retrieved - 1 limited-confidence finding(s) flagged for verification)

A.9. Case 38 — Stiff-Person Syndrome with GAD65 Antibodies, Thymic Carcinoid, and Autonomic Crises

Source case (verbatim)

Patient: 50 y/o F, BMI 23.8, Caucasian | Disciplines: Neurology, Endocrinology, Thoracic Surgery, Oncology, Rheumatology, Anesthesiology, Psychiatry, PM&R, Pharmacy

Active Disease States (20+)

SPS (anti-GAD65 strongly+); T1DM (shared GAD65 autoimmunity); thymic carcinoid (4.2 cm); autonomic crises (BP 240/140, diaphoresis, tachycardia); severe axial/limb rigidity; painful muscle spasms; gait disorder (hyperlordosis); frequent falls with fractures (hip, wrist); cerebellar ataxia (anti-GAD); temporal lobe epilepsy; Hashimoto thyroiditis; pernicious anemia; vitiligo; depression with agoraphobia; chronic pain; osteoporosis; insomnia; dysphagia (esophageal spasm); respiratory compromise (chest wall rigidity)

Clinical Presentation

Progressive trunk and limb rigidity x2 yr, now severe. Painful spasms triggered by startle/emotional stress causing falls (hip fracture 3 mo ago, wrist 6 wk ago). Autonomic crises with BP surging to 240/140 with diaphoresis — mimics pheochromocytoma but catecholamines normal. Anti-GAD65 >10,000. CT chest: 4.2 cm anterior mediastinal mass (thymic carcinoid). Gait: exaggerated lumbar lordosis, slow shuffling, cannot turn without support.

Key Laboratory / Imaging Data

Anti-GAD65 >10,000 IU/mL, anti-amphiphysin negative, EMG: continuous motor unit activity at rest, CT chest: 4.2 cm anterior mediastinal mass, biopsy: neuroendocrine carcinoma (carcinoid), glucose range 40-400 (brittle DM), HbA1c 8.8%, TSH 18, B12 <100, cortisol normal, catecholamines normal, DEXA T-score -3.2

Current Medications

Diazepam 10 mg TID (GABAergic first-line SPS), baclofen 20 mg TID, IVIG 2 g/kg monthly, rituximab (planned), insulin pump, levothyroxine, B12 monthly, gabapentin 600 TID (spasm adjunct), dantrolene PRN (severe spasms), alendronate, sertraline 100, melatonin

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:37:03.047Z
Files: Library case #38
Cases: 1

============================
CASE 1: 38
============================

Type: CASE 38
File: Library case #38 (pp. 39-39)
Demographics: 50
Diagnoses: B12 [B12], monthly, gabapentin 600 TID (spasm adjunct), dantrolene PRN (severe spa [B12], epilepsy, depression, anemia, osteoporosis, Hashimoto thyroiditis, pheochromocytoma, hypoglycemia, hyperkalemia, insomnia, chronic pain, diabetes mellitus, type 1 diabetes

REASONING CHAIN:
1. Case profile: 50 patient with working diagnoses of B12 [B12], monthly, gabapentin 600 TID (spasm adjunct), dantrolene PRN (severe spa [B12], epilepsy - 2 lab value(s), 8 medication(s) documented
2. Case-derived findings: 1 pattern identified (1 moderate/mild)
3. Evidence base: spans 1998-2017; 0 distinct methodology type(s) - 0 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 1 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Fever (50 C) [LIMITED CONFIDENCE]
   -> Infection workup — blood cultures, imaging, source identification
   ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:
1. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
   Rationale: Fever (50 C)
   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
2. [ROUTINE] Comprehensive medication reconciliation and interaction review for 8 agents
   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review
   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria
3. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application
   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician
   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:

- Retrieved evidence does not contain explicit recommendation-style statements. Proceed with established standard-of-care for B12 [B12], monthly, gabapentin 600 TID (spasm adjunct), dantrolene PRN (severe spa [B12], epilepsy, depression, anemia, osteoporosis, Hashimoto thyroiditis, pheochromocytoma, hypoglycemia, hyperkalemia, insomnia, chronic pain, diabetes mellitus, type 1 diabetes while consulting specialty-specific guidelines (IDSA, ACC/AHA, ADA, KDIGO, or others as applicable). [LIMITED]
- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (10 source(s) retrieved - 1 limited-confidence finding(s) flagged for verification)

A.10. Case 39 — Acquired Hemophilia A with Life-Threatening Hemorrhage, Mechanical Aortic Valve, and Occult Malignancy

Source case (verbatim)

Patient: 70 y/o F, BMI 24.2, Caucasian | Disciplines: Hematology, CT Surgery, Oncology, CC, Rheumatology, Vascular Surgery, Pharmacy

Active Disease States (20+)

Acquired hemophilia A (FVIII inhibitor 24 BU, no prior hemophilia); life-threatening hemorrhage (massive retroperitoneal hematoma, R thigh compartment syndrome); mechanical aortic valve (requires anticoagulation); supratherapeutic INR 3.2; suspected paraneoplastic trigger (lung mass 3.8 cm + mediastinal LAD); anemia (Hgb 4.8); aPTT >180s (unmeasurable); CHF (EF 40%); CKD 3; T2DM; HTN; afib; depression; chronic pain; immobilization — DVT risk

Clinical Presentation

Found with progressive bruising, then acute R thigh swelling and back pain. CT: massive retroperitoneal hematoma + R thigh compartment syndrome. INR 3.2 on warfarin. aPTT >180s. Mixing study: does not correct (inhibitor). FVIII <1%, inhibitor titer 24 BU. Hgb 4.8. Separately, CT chest: suspicious 3.8 cm lung mass + mediastinal LAD (likely malignancy triggering acquired hemophilia). Mechanical aortic valve — needs anticoagulation but she is hemorrhaging.

Key Laboratory / Imaging Data

FVIII <1%, inhibitor 24 BU, aPTT >180s, mixing study: no correction, INR 3.2, Hgb 4.8, Plt 210K, fibrinogen 280, CT: retroperitoneal hematoma + R thigh compartment, chest CT: 3.8 cm lung mass + LAD, Cr 1.8, BNP 2400, EF 40%

Current Medications

Bypassing agents (rFVIIa 90 mcg/kg q2h OR FEIBA 75 U/kg q8-12h), IV vitamin K + 4F-PCC (INR reversal but aPTT won't correct), warfarin held, immunosuppression to eradicate inhibitor: prednisone 1 mg/kg + rituximab (or CYC), pRBC transfusion, surgical fasciotomy consultation (R thigh — but coagulopathy)

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===
Generated: 2026-04-18T22:39:34.190Z
Files: Library case #39
Cases: 1

===========================

CASE 1: 39

==========================

Type: CASE 39
File: Library case #39 (pp. 40-40)
Demographics: 70
Diagnoses: DVT, CKD, depression, anemia, hemophilia, chronic pain, heart failure, hypertension, type 2 diabetes, chronic kidney disease, deep vein thrombosis

REASONING CHAIN:
1. Case profile: 70 patient with working diagnoses of DVT, CKD, depression - 5 lab value(s), 3 medication(s) documented
2. Case-derived findings: 3 patterns identified (1 critical, 1 high-severity, 1 moderate/mild)
3. Evidence base: spans 2012-2023; 0 distinct methodology type(s) - 0 evidence-linked statement(s) extracted
4. Case findings did not align directly with retrieved evidence - external verification required
5. 3 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.
6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:
- Elevated BNP (2400 pg/mL) [LIMITED CONFIDENCE]
    -> Suggests volume overload / heart failure; echo review recommended
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Severe anemia (Hgb 4.8 g/dL) [LIMITED CONFIDENCE]
    -> Transfusion threshold met in most settings; source evaluation needed
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended
- Fever (70 C) [LIMITED CONFIDENCE]
    -> Infection workup — blood cultures, imaging, source identification
    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:
1. [URGENT] Serial cardiac enzymes, 12-lead ECG, and consider echocardiography
   Rationale: Elevated BNP (2400 pg/mL): Suggests volume overload / heart failure; echo review recommended
   Resources: ACC/AHA ACS guidelines, TIMI/GRACE risk calculators
2. [IMMEDIATE] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)
   Rationale: Severe anemia (Hgb 4.8 g/dL): Transfusion threshold met in most settings; source evaluation needed
   Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure
3. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
   Rationale: Elevated BNP (2400 pg/mL)
   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
4. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
   Rationale: Severe anemia (Hgb 4.8 g/dL)
   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
5. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding
   Rationale: Fever (70 C)
   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling
6. [ROUTINE] Comprehensive medication reconciliation and interaction review for 3 agents
   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review
   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

7. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application
    Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician
    Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:
- Address Severe anemia (Hgb 4.8 g/dL) — Transfusion threshold met in most settings; source evaluation needed [Case-derived] [HIGH]
- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (9 source(s) retrieved - 3 limited-confidence finding(s) flagged for verification)

A.11. Case 40 — Transplant-Associated Thrombotic Microangiopathy with Chronic GVHD, Bronchiolitis Obliterans, and AIHA

Source case (verbatim)

Patient: 34 y/o F, BMI 20.8, mixed ethnicity | Disciplines: Hematology, Transplant Medicine, Nephrology, Pulmonology, Dermatology, GI, Hepatology, ID, CC, Pharmacy

Active Disease States (20+)

TA-TMA (post-allo BMT); chronic GVHD (skin, liver, lungs — BOS); warm AIHA; post-MUD allo-BMT for AML in CR2; CNI-associated TMA (cyclosporine); complement-mediated TMA (elevated sC5b-9); renal failure (Cr 4.2); MAHA (schistocytes, LDH 2400); Plt 22K; HTN (TMA-related); sclerodermatous skin GVHD with contractures; liver GVHD (Tbili 6.8); BOS (FEV1 32%); CMV reactivation; EBV viremia; AI (steroid taper); hypothyroidism; osteoporosis; depression; chronic pain; malnutrition; secondary immunodeficiency

Clinical Presentation

3 yr post-MUD allo-BMT for AML CR2. Developing worsening schistocytes, Plt drop to 22K, LDH 2400, Cr 1.6->4.2, new HTN 188/108. ADAMTS13 normal (61%) — not TTP. Cyclosporine trough 380 (supratherapeutic). Elevated sC5b-9 -> complement-mediated TMA. Concurrently: sclerodermatous skin GVHD with finger contractures, liver GVHD (Tbili 6.8, cholestatic), FEV1 declining (32%, BOS). CMV 14K, EBV 8K. Warm AIHA (DAT+ IgG, retic 8%, spherocytes on smear overlapping schistocytes).

Key Laboratory / Imaging Data

ADAMTS13 61% (normal), schistocytes 3+, spherocytes+, DAT+ (IgG warm), Plt 22K, Hgb 6.4, retic 8%, LDH 2400, haptoglobin <10, Cr 4.2, cyclosporine 380, sC5b-9 elevated, C3 68 (low), Tbili 6.8, ALP 420, FEV1 32%, CMV 14K, EBV 8K, skin bx: sclerodermatous GVHD

Current Medications

Cyclosporine -> switch to ruxolitinib (GVHD + eliminates CNI-TMA trigger), prednisone 0.5 mg/kg (GVHD), eculizumab (complement-mediated TMA if confirmed), valganciclovir (CMV), rituximab (planned for EBV + AIHA), IVIG q4wk, inhaled budesonide/formoterol + azithromycin (BOS), photopheresis (skin GVHD), PT/OT (contractures), topical tacrolimus, ursodiol, Ca+D

Machine-generated Clinical Inference Report (verbatim)

=== CLINICAL INFERENCE REPORT ===

===========================

CASE 1: 40

===========================

Type: CASE 40

File: Library case #40 (pp. 41-41)

Demographics: 34

Diagnoses: depression, TTP, AML, osteoporosis, hypothyroidism, chronic pain, hypertension, gastrointestinal, acute myeloid leukemia

REASONING CHAIN:

1. Case profile: 34 patient with working diagnoses of depression, TTP, AML - 4 lab value(s), 9 medication(s) documented

2. Case-derived findings: 2 patterns identified (1 critical, 1 high-severity, 0 moderate/mild)

3. Evidence base: spans 2015-2020; 0 distinct methodology type(s) - 0 evidence-linked statement(s) extracted

4. Case findings did not align directly with retrieved evidence - external verification required

5. 2 finding(s) flagged for verification: evidence retrieved did not directly address these elements. Recommendations based on general clinical principles until verified against specialty resources.

6. Overall: evidence base insufficient for definitive inference; treat output as hypothesis-generating pending verification

INFERENTIAL FINDINGS:

- Severe anemia (Hgb 6.4 g/dL) [LIMITED CONFIDENCE]

    -> Transfusion threshold met in most settings; source evaluation needed

    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

- Severe thrombocytopenia (Plt 22 K/uL) [LIMITED CONFIDENCE]

    -> Bleeding risk; consider HIT if on heparin, medication-induced, hematologic process

    ! Retrieved evidence base did not address this finding directly — independent verification through Lexicomp, UpToDate, or specialty-specific guidelines recommended

RECOMMENDED VERIFICATION STEPS:

1. [IMMEDIATE] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)

   Rationale: Severe anemia (Hgb 6.4 g/dL): Transfusion threshold met in most settings; source evaluation needed

   Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure

2. [URGENT] Repeat CBC and coagulation panel, type and cross if transfusion likely, source evaluation (GI workup, etc.)

   Rationale: Severe thrombocytopenia (Plt 22 K/uL): Bleeding risk; consider HIT if on heparin, medication-induced, hematologic process

   Resources: Transfusion medicine guidelines (AABB), HIT 4T score if heparin exposure

3. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Severe anemia (Hgb 6.4 g/dL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

4. [ROUTINE] Verify management approach via specialty-specific resources — retrieved evidence base did not directly address this finding

   Rationale: Severe thrombocytopenia (Plt 22 K/uL)

   Resources: UpToDate, DynaMed, Specialty society guidelines, Lexicomp/Micromedex, DailyMed for current product labeling

5. [ROUTINE] Comprehensive medication reconciliation and interaction review for 9 agents

   Rationale: Polypharmacy (>=3 agents) warrants systematic DDI and appropriateness review

   Resources: Drugs.com Interaction Checker, Lexi-Interact, Beers Criteria (if age >=65), STOPP/START criteria

6. [ROUTINE] Cross-verify all recommendations against institutional protocols, current product labeling (DailyMed), and specialty-specific guidelines before clinical application
   Rationale: AuditMed outputs are for research and educational use; clinical decisions remain the responsibility of the treating clinician
   Resources: Institutional clinical practice guidelines, DailyMed FDA labeling, Specialty society consensus documents

EVIDENCE-BASED RECOMMENDATIONS:
- Address Severe anemia (Hgb 6.4 g/dL) — Transfusion threshold met in most settings; source evaluation needed [Case-derived] [HIGH]
- Verify all therapeutic changes against current product labeling (DailyMed), institutional formulary, and patient-specific factors (allergies, organ function, goals of care) before implementation. [N/A]

GRADE: LOW (8 source(s) retrieved - 2 limited-confidence finding(s) flagged for verification)

AuditMed: A Single-File, Browser-Based Clinical Evidence Audit Platform — Architecture, Stress-Test Results, and Proposed Applications in Drug Informatics and Pharmacy Education

David J. Ferguson, MS, BCMAS, MRSC, MRSB, RSci

Correspondence: david.ferguson@bison.howard.edu • Platform: https://auditmed9.onrender.com/

Scope of This Supplement

This supplement accompanies the main manuscript and contains the AuditMed platform user guide. The user guide is presented separately here, rather than in the main manuscript body, so that the main manuscript remains focused on platform description, stress-test methodology, results, and proposed applications. The user guide is intended for readers who wish to reproduce the stress-test reported in Section 4 of the main manuscript or who plan to use AuditMed in educational or drug-informatics practice. Section S1 covers account creation and login. Section S2 covers the PharmSearch Pro literature-search workflow. Section S3 covers the Clinical Acumen case-ingestion and one-click inference workflow. Section S4 covers the Configure panel. Section S5 covers administrative tasks. Section S6 covers common troubleshooting scenarios.

S1. Account Creation and Login

S1.1 Accessing the platform

AuditMed is hosted at https://auditmed9.onrender.com/. The platform is available without installation; any modern browser (Chromium-based browsers, Firefox, or Safari) in a desktop or tablet configuration is supported. Mobile phone viewports function but are not the intended form factor because tabular output is difficult to read below approximately 768 pixels wide.

S1.2 Creating an account

Click Sign Up on the landing page. Enter an email address, choose a password, and confirm the password. The platform sends a verification email; clicking the link in that email activates the account. An institutional email address is preferred where available because verification of institutional affiliation supports the educational-use designation.

S1.3 Signing in

On return visits, click Sign In, enter the email and password used at registration, and click Continue. Sessions remain active for the duration of the browser tab. Closing the tab ends the session; case data persisted in the browser IndexedDB remain available on next login.

S1.4 Password reset

If the password is forgotten, click Forgot Password on the sign-in panel, enter the registered email address, and follow the link sent to that address to choose a new password. Password-reset tokens expire after one hour.

S2. PharmSearch Pro: Literature Search Workflow

S2.1 Entering a clinical question

From the main navigation, select PharmSearch Pro. Enter the clinical question in the query field at the top of the module. Questions may be entered in natural language ("What is the efficacy of SGLT2 inhibitors in heart failure with preserved ejection fraction?") or in a more structured PICO-style format. The query parser is tolerant of both styles; keyword expansion occurs automatically at Stage 1.

S2.2 Running the six-stage pipeline

Click Run Pipeline. The platform executes the Search → Select → Parse → Analyze → Infer → Create pipeline end-to-end. Intermediate stages are visible in a progress panel; the panel reports the number of sources retrieved from each of the nineteen integrated APIs in real time.

S2.3 Reviewing auto-selected sources

At the Stage-4.5 checkpoint, the platform displays the auto-selected top-N sources with per-source metadata (source tier, publication year, methodology classification, access link). Users may deselect sources considered off-topic or add sources from the larger retrieval pool. Clicking Continue after review passes the refined source set to the synthesis stage.

S2.4 Choosing an output format

At the Create stage, nine output formats are available: Systematic Review, Narrative Review, Drug Monograph, Clinical Summary, Interaction Report, Formulary Evaluation, Patient Education Handout, Consult Response, and Mechanism Overview. Each format populates a distinct template from the same retrieved and synthesized evidence base.

S2.5 Export and citation

Completed outputs may be exported as plain text, Markdown, or copied to the clipboard. Citations are preserved in a uniform bracketed-number style with a fully populated reference list at the end of each export. PubMed identifiers, DOIs, and direct URLs are included in the reference list where available.

S3. Clinical Acumen: Case Ingestion and One-Click Inference

S3.1 Uploading a case document

From the main navigation, select Clinical Acumen. Click Upload Case and select a PDF or plain-text file containing the patient case. The platform performs text extraction, de-identification (Section 2.5 of the main manuscript), and structured parsing. Extracted fields appear in an editable preview pane so that the user may correct parsing errors before saving the case.

S3.2 Multi-case documents

If the uploaded document contains more than one case (for example, a teaching file with many cases in sequence), the ingestion pipeline attempts to segment the document. Each detected case is presented as a separate library entry; the user may merge, split, or delete entries before saving.

S3.3 Saving to the case library

After review, click Save to Library. The case is stored in the browser-local IndexedDB of the current device. Cases are not transmitted to any server and are not shared across devices. To transfer a case to a different device, export it using the Export menu and re-import on the target device.

S3.4 Running one-click inference

From the case-library panel, select one or more cases and click Run Inference. For a single case, the platform executes the full Clinical Inference Report workflow: clinical-finding extraction, evidence retrieval tied to the parsed diagnosis list, evidence–finding matching, inferential-finding composition, verification-step generation, and report assembly. For multiple cases selected simultaneously, reports are generated sequentially and collected into a single batch output.

S3.5 Reading the Clinical Inference Report

Each Clinical Inference Report contains six standard sections: reasoning chain (a six-step audit of how the report was composed), inferential findings (each labeled with a confidence tag and evidence source references), recommended verification steps (priority-tagged: IMMEDIATE, URGENT, or ROUTINE, each with rationale and resource pointers), evidence-based recommendations (each with an evidence-quality tag), the overall GRADE tier, and the reference list used during composition. Appendix A of the main manuscript reproduces eleven such reports verbatim.

S3.6 Exporting the report

Click Export Report to save the Clinical Inference Report as plain text or Markdown. The exported file contains the full reasoning chain and is suitable for inclusion in portfolio artefacts, rotation deliverables, or educational discussion materials.

S4. Configure Panel

S4.1 LLM augmentation (optional)

By default, AuditMed uses the AuditMed Evidence Engine (AEE), a deterministic in-browser NLP synthesis engine. Users may optionally supply a Google Gemini or Groq API key to enable LLM-augmented narrative synthesis at the Create stage. The API key is stored in browser-local storage of the current device and is never transmitted to AuditMed servers. To clear a saved key, open the Configure panel, click Clear LLM Credentials, and confirm.

S4.2 DrugBank Clinical API (optional)

If the user has a DrugBank Clinical API key, it may be entered in the Configure panel to unlock deeper drug-metadata retrieval. Without a key, the platform defaults to the free UniChem identifier-resolution pathway, which provides cross-identifier mapping but narrower clinical metadata.

S4.3 Output-format defaults

The Configure panel allows the user to set a default output format for PharmSearch Pro so that the same format is auto-selected at the Create stage in future queries. Defaults for source top-N at Stage 2 and for verification-step priority thresholds are also adjustable, though most users will leave these at factory settings.

S4.4 Clearing stored data

The Configure panel provides controls to clear browser-local data: saved LLM credentials, saved cases in the case library, and cached API responses. Clearing saved cases is irreversible; export any cases to be retained before clicking Clear Case Library.

S5. Administrative Tasks

S5.1 Reviewing usage analytics

Administrative accounts have access to a usage-analytics dashboard showing aggregate, de-identified usage patterns across the platform: total pipeline runs per week, distribution of output formats selected, and average source count per retrieval. Identifiable user data are not available to administrators. The dashboard is intended to support capacity planning and to guide development prioritization, not to evaluate individual users.

S5.2 Platform status and uptime

Platform status is visible at the bottom of the main navigation panel.

S6. Troubleshooting

S6.1 Pipeline appears to stall at the Search stage

One or more of the nineteen integrated APIs may be temporarily unavailable. The platform times out unresponsive APIs at 30 seconds and continues with the remaining sources; a timed-out API is noted in the retrieval report. If pipeline progression is stalled for more than two minutes, refresh the browser tab and retry. Persistent stalls should be reported via the Contact link at the bottom of the main navigation.

S6.2 Case parsing leaves fields blank

The PDF text extractor cannot parse scanned images without optical character recognition. If a case PDF is a scan (no selectable text in a PDF reader), convert it to a text-searchable PDF using an OCR tool before upload. If parsing is incomplete on a text-searchable PDF, edit the fields manually in the preview pane before saving to the library.

S6.3 "Fever (XX°C)" appears in an inference report where no fever is present

This is the age-as-fever parser defect documented in Section 4.3 of the main manuscript. The patient's age in years is being misclassified as a body-temperature reading. The defect is under active revision. As a workaround pending the fix, manually remove the spurious finding and the associated verification step from the exported report.

S6.4 Medication substrings appear in the diagnosis list

This is the diagnosis-versus-medication parsing defect documented in Section 4.3 of the main manuscript. It is most likely when the source case contains medication information in a free-text paragraph rather than a structured list. As a workaround pending the fix, edit the parsed diagnosis field in the case-preview pane before saving the case.

S6.5 LLM-augmented synthesis returns an error

Verify that the API key entered in the Configure panel is current and has available quota. If the key is valid but errors persist, clear the saved key, re-enter it, and retry. If errors persist after re-entry, disable LLM augmentation and run the pipeline in AEE-only mode; AEE-only mode is fully functional and is the factory default.

S6.6 Exported file is empty

Confirm that the pipeline completed through the Create stage before export. A partial pipeline (for example, stopped at Stage-4.5 review) will export only the sources reviewed so far, not a full synthesis. Re-run the pipeline through completion before export.

S7. Contact and Feedback

Questions, bug reports, and collaboration inquiries may be directed to the corresponding author at david.ferguson@bison.howard.edu. Feedback from educational deployments is particularly welcome and will inform the roadmap items described in Section 7.2 of the main manuscript.